Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), ...
Sionna Therapeutics is a clinical-stage biotechnology company focused on cystic fibrosis (CF), a genetic disease caused by mutations in the CFTR gene. CFTR encodes an ion channel that regulates the movement of salt and fluids across cell membranes. Defective CFTR function can produce thick, sticky mucus and progressive damage in ...Sionna Therapeutics is a clinical-stage biotechnology company focused on cystic fibrosis (CF), a genetic disease caused by mutations in the CFTR gene. CFTR encodes an ion channel that regulates the movement of salt and fluids across cell membranes. Defective CFTR function can produce thick, sticky mucus and progressive damage in the lungs, pancreas, and other organs. Sionna’s central objective is to develop medicines that more comprehensively restore CFTR activity and potentially improve upon limitations associated with existing treatment approaches.
The company was founded in 2019 and is headquartered at 21 Hickory Drive, Suite 500, Waltham, Massachusetts. Its chief executive officer is Michael Cloonan. Publicly available company information also identifies Mark Munson, Ph.D., as a co-founder and scientific leader associated with the company’s formation and research efforts. Sionna operates with a relatively small workforce of approximately 59 full-time employees, consistent with a focused clinical-stage biotechnology model that relies on specialized research, development, regulatory, and clinical capabilities rather than large-scale commercial operations.
Sionna’s product strategy centers on CFTR modulators and a proprietary portfolio of compounds designed to address multiple functional regions of the CFTR protein. Its programs include NBD1 stabilizers and complementary modulators directed at NBD1, ICL4, and TMD1. NBD1 is an important structural and functional region of CFTR, and stabilizing it may help correct defects caused by certain mutations. By combining compounds with complementary mechanisms, the company aims to develop treatment regimens capable of improving CFTR folding, processing, trafficking, and channel activity across broader patient populations.
As a clinical-stage company, Sionna does not appear to have meaningful commercial product revenue in the supplied trailing-twelve-month data. The company reports research and development-driven losses and negative operating cash flow, which are typical for a biotechnology business conducting pre-commercial drug discovery and clinical trials. Its financial resources, including cash and working capital, are important for funding laboratory research, manufacturing, regulatory preparation, and human clinical studies. The company may need additional capital through equity offerings, partnerships, licensing transactions, or other financing activities before its programs generate product revenue.
Sionna completed its initial public offering in February 2025 and is listed on Nasdaq under SION. Its long-term prospects depend on the clinical efficacy and safety of its CFTR programs, the ability to enroll and complete trials, regulatory outcomes, manufacturing execution, competitive differentiation, and the availability of sufficient funding. The company’s broader ambition is to offer differentiated CF medicines that normalize CFTR function and expand effective treatment options for people living with cystic fibrosis.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-75.3M
-22.0%
-11.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-66.7M
-26.2%
-101.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
2.8%
+147.5%
+4.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
20.61x
+42.2%
-11.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
